Compare
RxSight, Inc. vs Staar Surgical Co vs Cooper Companies, Inc. vs Bausch & Lomb Corp
| Latest fiscal year | RxSight, Inc. RXST | Staar Surgical Co STAA | Cooper Companies, Inc. COO | Bausch & Lomb Corp BLCO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-01-02 | 2025-10-31 | 2025-12-31 |
| Revenue | $134.48M | $239.44M | $4.09B | $5.10B |
| Revenue growth (YoY) | -3.9% | -23.7% | +5.1% | +6.5% |
| Gross margin | 76.6% | 76.2% | 65.5% | n/a |
| Operating margin | -35.8% | -38.3% | 16.7% | 2.2% |
| Net margin | -29.0% | -33.6% | 9.2% | -7.1% |
| Net income | -$38.94M | -$80.45M | $374.90M | -$360.00M |
| EPS (Diluted) | -$0.95 | -$1.62 | $1.87 | -$1.02 |
| Operating cash flow | -$15.51M | -$34.23M | $796.10M | $283.00M |
| Free cash flow | -$19.34M | -$40.05M | $433.70M | -$66.00M |
| Cash & equivalents | $19.95M | $153.15M | $110.60M | $383.00M |
| Total assets | $311.81M | $451.68M | $12.39B | $14.02B |
| Total liabilities | $36.13M | $107.49M | $4.16B | $7.50B |
| Shareholders' equity | $275.68M | $344.18M | $8.24B | $6.52B |
| Return on year-end equity | -14.1% | -23.4% | 4.6% | -5.5% |
| Shares outstanding | 41.24M | 49.40M | 195.90M | 354.21M |
Revenue, most recent five fiscal years
| Fiscal year | RxSight, Inc. | Staar Surgical Co | Cooper Companies, Inc. | Bausch & Lomb Corp |
|---|---|---|---|---|
| Latest | $134.48M Ended 2025-12-31 | $239.44M Ended 2026-01-02 | $4.09B Ended 2025-10-31 | $5.10B Ended 2025-12-31 |
| 1 year earlier | $139.93M Ended 2024-12-31 | $313.90M Ended 2024-12-27 | $3.90B Ended 2024-10-31 | $4.79B Ended 2024-12-31 |
| 2 years earlier | $89.08M Ended 2023-12-31 | $322.42M Ended 2023-12-29 | $3.59B Ended 2023-10-31 | $4.15B Ended 2023-12-31 |
| 3 years earlier | $49.01M Ended 2022-12-31 | $239.44M Ended 2022-12-30 | $3.31B Ended 2022-10-31 | $3.77B Ended 2022-12-31 |
| 4 years earlier | $22.59M Ended 2021-12-31 | $230.47M Ended 2021-12-31 | $2.92B Ended 2021-10-31 | $3.77B Ended 2021-12-31 |